B
Bénédicte Neven
Researcher at University of Paris
Publications - 280
Citations - 12503
Bénédicte Neven is an academic researcher from University of Paris. The author has contributed to research in topics: Medicine & Transplantation. The author has an hindex of 52, co-authored 215 publications receiving 9328 citations. Previous affiliations of Bénédicte Neven include Necker-Enfants Malades Hospital & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Gene Therapy in a Patient with Sickle Cell Disease.
Jean-Antoine Ribeil,Salima Hacein-Bey-Abina,Emmanuel Payen,Alessandra Magnani,Michaela Semeraro,Elisa Magrin,Laure Caccavelli,Bénédicte Neven,Philippe Bourget,Wassim El Nemer,Pablo Bartolucci,Leslie Weber,Hervé Puy,Jean-François Meritet,David Grevent,Yves Beuzard,Stany Chrétien,Thibaud Lefebvre,Robert W. Ross,Olivier Negre,Gabor Istvan Veres,Laura Sandler,Sandeep Soni,Mariane de Montalembert,Stéphane Blanche,Philippe Leboulch,Marina Cavazzana +26 more
TL;DR: First patient treated with lentiviral vector–mediated addition of an antisickling β‐globin gene into autologous hematopoietic stem cells without recurrence of sickle crises and with correction of the biologic hallmarks of the disease is described.
Journal ArticleDOI
Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations
Nadia Jeremiah,Bénédicte Neven,Matteo Gentili,Isabelle Callebaut,Sophia Maschalidi,Marie-Claude Stolzenberg,Nicolas Goudin,Marie-Louis Frémond,Patrick Nitschke,Thierry Jo Molina,Stéphane Blanche,Capucine Picard,Gillian I. Rice,Yanick J. Crow,Nicolas Manel,Alain Fischer,Brigitte Bader-Meunier,Frédéric Rieux-Laucat +17 more
TL;DR: It is found that the STING mutant spontaneously localizes in the Golgi of patient fibroblasts and is constitutively active in the absence of exogenous 2'3'-cGAMP in vitro.
Journal ArticleDOI
Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: Entering a new century, do we do better?
Andrew R. Gennery,Andrew R. Gennery,Mary Slatter,Mary Slatter,Laure Grandin,Pierre Taupin,Andrew J. Cant,Paul Veys,Persis Amrolia,H. Bobby Gaspar,E. Graham Davies,Wilhelm Friedrich,Manfred Hoenig,Luigi D. Notarangelo,Evelina Mazzolari,Fulvio Porta,Robbert G. M. Bredius,A.C. Lankester,Nico M Wulffraat,Reinhard Seger,Tayfun Güngör,Anders Fasth,Petr Sedlacek,Bénédicte Neven,Stéphane Blanche,Alain Fischer,Marina Cavazzana-Calvo,Paul Landais +27 more
TL;DR: Individual disease categories now need to be analyzed so that disease-specific prognosis may be better understood and the best treatments planned, despite improvements in each group.
Journal ArticleDOI
A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency
Salima Hacein-Bey-Abina,Sung-Yun Pai,H. Bobby Gaspar,Myriam Armant,Charles C. Berry,Stéphane Blanche,Jack J. Bleesing,Johanna Blondeau,Helen de Boer,Karen F. Buckland,Laure Caccavelli,Guilhem Cros,Satiro N. De Oliveira,Karen S. Fernandez,Dongjing Guo,Chad E. Harris,Gregory Hopkins,Leslie Lehmann,Annick Lim,Wendy B. London,Johannes C.M. Van der Loo,Nirav Malani,Frances Male,Punam Malik,M. Angélica Marinovic,Anne Marie McNicol,Despina Moshous,Bénédicte Neven,Matias Oleastro,Capucine Picard,Jerome Ritz,Christine Rivat,Axel Schambach,Kit L. Shaw,Eric A. Sherman,Leslie E. Silberstein,Emmanuelle Six,Fabien Touzot,Alla V. Tsytsykova,Jinhua Xu-Bayford,Christopher Baum,Frederic D. Bushman,Alain Fischer,Donald B. Kohn,Alexandra H. Filipovich,Luigi D. Notarangelo,Marina Cavazzana,David A. Williams,Adrian J. Thrasher +48 more
TL;DR: This modified γ-retrovirus vector was found to retain efficacy in the treatment of SCID-X1 and the long-term effect of this therapy on leukemogenesis remains unknown.
Journal ArticleDOI
Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review
Nienke M. ter Haar,Helen J. Lachmann,Seza Ozen,P Woo,Yosef Uziel,Consuelo Modesto,Isabelle Koné-Paut,Luca Cantarini,Antonella Insalaco,Bénédicte Neven,Michael Hofer,Donato Rigante,Sulaiman M. Al-Mayouf,Isabelle Touitou,Romina Gallizzi,Efimia Papadopoulou-Alataki,Silvana Martino,Jasmin B Kuemmerle-Deschner,Laura Obici,Nicolae Iagaru,Anna Simon,Susan Nielsen,Alberto Martini,Nicolino Ruperto,Marco Gattorno,Joost Frenkel +25 more
TL;DR: Evaluating the response to treatment of autoinflammatory diseases from an international registry and an up-to-date literature review found that colchicine is the treatment of choice for FMF and IL-1 blockade for DIRA and CAPS and Corticosteroids on demand probably represent a valid therapeutic strategy for PFAPA, but also for MKD and TRAPS.